Keymed-Innocare JV Signs Commercial License Deal for Anti-Tumor Drug
MT Newswires Live01-21
A joint venture with Keymed Biosciences (HKG:2162) and InnoCare (HKG:9969, SHA:688428) unit Beijing InnoCare Pharma Tech signed a license agreement with Prolium to develop the CM355 drug for tumors.
Under the license deal, Prolium will obtain exclusive rights to develop, register, manufacture, and commercialize the drug outside of Asia, according to a Monday filing with the Hong Kong Exchange.
Keymed's Chengdu unit and Innocare Unit Beijing InnoCare will be entitled to upfront and near-term payments of $17.5 million, up to $502.5 million in additional payments, and tiered royalties on net sales from Prolium based on their respective interests in the Beijing Tiannuojiancheng Pharma Tech joint venture.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
